Roquinimex (Standard)
Roquinimex (Standard) is the analytical standard of Roquinimex (HY-13743). Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 84088-42-6
- Formel: C18H16N2O3
- Molecular Weight:308.33
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Reinheit & Dokumentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS. Nr. 84088-42-6
-
Molecular Weight 308.33
-
Formel C18H16N2O3
-
SMILES
O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2)N(C)C3=CC=CC=C3
-
Synonyms
Linomide (Standard); FCF89 (Standard); ABR212616 (Standard)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Ohsuga Y, et al. Dermatologic changes associated with roquinimex immunotherapy after autologous bone marrow transplant. J Am Acad Dermatol. 2000;43(3):437-441. [Content Brief]
[2]. Liu Q, et al. Roquinimex inhibits dextran sodium sulfate-induced murine colitis. Inflamm Res. 2003 Feb;52(2):64-8. [Content Brief]
[3]. Tian WZ, et al. Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. Acta Neurol Scand. 1998 Aug;98(2):94-101. [Content Brief]
[4]. Mackean MJ, et al. A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma. Br J Cancer. 1998;78(12):1620-1623. [Content Brief]
[5]. Hasan AM, et al. Novel effect of topical Roquinimex and its combination with Clobetasol on an imiquimod-induced model of psoriasis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(7):5219-5232. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Roquinimex (Standard) Related Classifications
HY-13743R Related Classifications
Powered by Bioz
- Roquinimex (Standard)
- 84088-42-6
- Linomide (Standard)
- FCF89 (Standard)
- ABR212616 (Standard)
- Reference Standards
- TNF Receptor
- Interleukin Related
- IFNAR
- acute myelogenous leukemia
- inflammatory bowel disease
- NK cell
- chronic myelogenous leukemia
- TH1 lymphocyte cytokines
- multiple sclerosis
- advanced renal cell carcinoma
- advanced malignant melanoma
- eccrine sweat gland
- TH2 lymphocyte cytokines
- Inhibitor
- inhibitor
- inhibit